Peterson Wealth Services Buys 453 Shares of Edwards Lifesciences Co. (NYSE:EW)

Peterson Wealth Services raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,783 shares of the medical research company’s stock after purchasing an additional 453 shares during the period. Peterson Wealth Services’ holdings in Edwards Lifesciences were worth $354,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Alpha Financial Partners LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at about $693,000. CHICAGO TRUST Co NA boosted its stake in shares of Edwards Lifesciences by 28.5% in the third quarter. CHICAGO TRUST Co NA now owns 6,232 shares of the medical research company’s stock worth $411,000 after acquiring an additional 1,383 shares during the period. Koshinski Asset Management Inc. bought a new position in shares of Edwards Lifesciences in the third quarter worth about $396,000. Martin Capital Advisors LLP boosted its stake in shares of Edwards Lifesciences by 0.7% in the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock worth $1,686,000 after acquiring an additional 186 shares during the period. Finally, Elk River Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 1.3% in the third quarter. Elk River Wealth Management LLC now owns 74,163 shares of the medical research company’s stock worth $4,894,000 after acquiring an additional 950 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.0 %

Shares of NYSE EW opened at $71.05 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The business’s 50 day moving average price is $72.45 and its 200-day moving average price is $69.18. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market cap of $41.91 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 3.64 and a beta of 1.10.

Analyst Ratings Changes

EW has been the subject of a number of recent analyst reports. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Piper Sandler dropped their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Barclays upped their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, The Goldman Sachs Group increased their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $79.19.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,000 shares of company stock worth $547,430. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.